Background {#Sec1}
==========

Hyperinsulinaemic hypoglycaemia (HH) is a group of clinically and genetically heterogeneous disorders characterized by dysregulation of insulin secretion by pancreatic β-cells \[[@CR1]\]. Early diagnosis and treatment is important to prevent permanent brain damage \[[@CR2]\]. HH can be either transient or persistent; transient forms of HH are usually secondary to conditions such as maternal diabetes mellitus or intra-uterine growth retardation \[[@CR1]\]. The incidence of HH can vary from 1 in 35,000--40,000 in the general population \[[@CR3]\] to 1 in 2,500 in some communities with high rates of consanguinity \[[@CR4]\].

The clinical presentation can be varied ranging from completely asymptomatic, mild disease to severe disease unresponsive to medication needing surgical intervention \[[@CR5]\]. The HH due to recessive mutations in *ABCC8/KCNJ11* is usually severe and requires high concentrations of intravenous glucose to maintain normoglycaemia \[[@CR5]\]. Hypoglycemic symptoms may vary from being non-specific (such as poor feeding, lethargy and irritability) to severe (such as apnea, seizures or coma). Macrosomia is a common feature in infants, but not all babies with HH are macrosomic \[[@CR6]\]. There are two histological subtypes of CHI: diffuse and focal \[[@CR7]\]. The diffuse form is inherited in an autosomal recessive (or dominant) manner whereas the focal form is sporadic in inheritance. The first line of medical therapy in HH includes diazoxide, which binds to the intact SUR1 component of the K~ATP~ channels and prevents depolarization of the β-cell membrane and insulin secretion \[[@CR1]\].

HH is caused by mutations in the key genes that are involved in regulation of insulin secretion from the pancreatic β-cells. So far, mutations in *ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1, HNF4A, UCP2* and *HNF1A* have been identified to be involved in the pathogenesis of HH \[[@CR1], [@CR8]\]. The most common causes of diffuse medically unresponsive HH are mutations in *ABCC8* and *KCNJ11*. These two genes encode for the SUR1 (sulphonylurea receptor 1 subunit) and Kir6.2 (inward-rectifying potassium channel pore-forming subunit) proteins, respectively which constitute the K~ATP~ channel of the pancreatic β-cell membrane \[[@CR2]\].

The inactivating mutations in *ABCC8/KCNJ11* reduce or completely abolish the activity of the K~ATP~ channel, leading to unregulated insulin release despite severe hypoglycaemia \[[@CR9]\]. The recessive inactivating mutations in *ABCC8* and *KCNJ11* usually cause severe HH, which is unresponsive to medical treatment with diazoxide. The molecular basis of recessive inactivating *ABCC8* and *KCNJ11* mutations involve defects in K~ATP~ channel biogenesis and turnover, channel trafficking from the ER and Golgi apparatus to the plasma membrane and alterations of channels in response to nucleotide regulation and open state frequency \[[@CR10]\]. Dominant inactivating mutations in *ABCC8* and *KCNJ11* usually cause HH with a milder phenotype \[[@CR11]\].

Hyperinsulinism--hyperammonaemia syndrome (HI/HA), the second most common form of HH is associated with activating missense mutations in *GLUD1*, which encodes the mitochondrial matrix enzyme, glutamate dehydrogenase (GDH). Patients present with recurrent symptomatic postprandial hypoglycaemia following protein-rich meals (leucine-sensitive hypoglycaemia) as well as fasting hypoglycaemia accompanied by asymptomatic elevations of plasma ammonia \[[@CR12]\]. Mutations in *HNF4A, HNF1A* and *GCK* cause maturity-onset diabetes of the young (MODY) as well HH \[[@CR8], [@CR13]\].

Mutations in the mitochondrial *HADH* gene (encoding the enzyme L-3-hydroxyacyl-coenzyme A dehydrogenase, HADH), are a rare cause of HH \[[@CR14]\]. This enzyme catalysis the conversion of L3-hydroxyacyl-CoAs of variable chain length to their corresponding 3-ketoacyl-CoAs and exerts highest activity to 3-hydroxybutyryl-CoA. *HADH* mutations can lead either to severe neonatal HH or to mild late onset HH \[[@CR15]\]. All patients reported so far have responded to diazoxide and some had abnormal acylcarnitine metabolites (raised plasma hydroxybutyrylcarnitine and urinary 3-hydroxyglutarate levels). Protein sensitivity has been demonstrated in patients with HADH mutations \[[@CR16]\] and this has been confirmed in the HADH knockout mouse \[[@CR17]\]. However the precise mechanism of dysregulated insulin secretion in patients with a HADH deficiency is not understood but might involve an interaction between GDH and HADH \[[@CR17]\]. Genetic analysis for HADH gene is recommended in patients with diazoxide responsive HH from consanguineous families, who are negative for mutations in the K~ATP~ channels \[[@CR18]\].

Although clinical characteristics and genetic etiology of HH patients have been described in some studies \[[@CR19]--[@CR21]\], little is known about HH in the Iranian population with a high rate of consanguineous marriages \[[@CR22]\]. The aim of this study was to investigate genotype/phenotype correlations in a sample of Iranian patients with HH from Isfahan.

Methods {#Sec2}
=======

In this cross-sectional study, we collected data on the patients who visited the pediatric endocrinology outpatient clinics and the infants who were referred to Al-Zahra Hospital from September 1998 to July 2012. All infants and children were diagnosed with HH based on clinical and biochemical criteria \[[@CR2]\]. Patients with a secondary cause of HH such as perinatal asphyxia, prematurity, intra-uterine growth restriction, and syndromic forms were excluded. The clinical data included age at presentation, birth weight, medications, neonatal history, epilepsy and neurological deficits, family history, history of hypoglycaemia following protein-rich meals and consanguinity of parents. Serum ammonia level was checked in all patients.

Children were defined as being responsive to diazoxide when (a) feeding with normal frequency and volume (b) able to fast appropriately for age and maintain normal blood glucose levels (c) serum insulin level low or undetectable at the end of the fast (d) appropriate increase in serum fatty acids and ketone bodies at the end of the fast \[[@CR2]\]. Diazoxide-unresponsive patients either underwent near total pancreatectomy or were managed with combinations of octreotide and diazoxide along with high calorie feeds.

Written informed consent for genetic tests was obtained from parents of all patients. The study was reviewed and approved by the Ethical Committee of Isfahan University of Medical Sciences.

Genomic DNA was extracted from peripheral leukocytes using standard procedures. All exons and intron--exon boundaries of *ABCC8, KCNJ11, HADH, GLUD1, HNF4A* and *GCK* genes were amplified by PCR. The products were sequenced using a BigDye Terminator v3.1 Cycle sequencing Kit on an ABI 3730XL Analyzer (Applied Biosystems, Foster City, CA, USA) and sequences were compared with the reference sequence (NM_000525 for KCNJ11, NM_000352.3 for ABCC8, and NM_000162.3 for GCK) using Chromas (V.2.01, Technelysium Pty Ltd, Tewantin QLD, Australia) or Mutation Surveyor software V3.24 (Softgenetics, State College, PA, USA). Mutation testing was done on parental samples when a mutation was identified in the child. If no mutation was identified, testing for a partial/whole gene deletion was undertaken using multiplex ligation-dependent probe amplification (MLPA).

Statistical analysis {#Sec3}
--------------------

Data are presented as mean ± standard deviation and frequency. The independent sample t test was used to assess continuous variables between two groups. The Mann--Whitney test was used for data that were not normally distributed. Analyses were performed using SPSS (IL, USA, version 19.0). Significant level was set as P \< 0.05.

Results {#Sec4}
=======

Twenty-three patients with HH with age ranging from 1 month to 21 years were included in this study. One patient with achondroplasia and three children with secondary HH due to intra-uterine growth restriction were excluded. The age at presentation ranged from neonatal period (day 1 of life) to 3 years. Eleven (47 %) of the patients were noted to be symptomatic within the first 48 h after birth. The most common clinical symptom was seizure (82 %). All patients except two children were born at full term. The mean birth weight was 3,423 ± 757 g (with a range of 1,700--5,000 g). Only five patients (21 %) were macrosomic. Ten (43 %) of patients were female. 12 (52 %) children with HH were born to consanguineous couples. Two families had two affected children.

A high frequency (30 %) of neurodevelopmental delay was observed in these patients. Furthermore, 12 (52 %) patients suffered from epilepsy. None of the patients had hyperammonemia.

A total number of 18 (78 %) patients responded to diazoxide. Five diazoxide-unresponsive patients underwent near total pancreatectomy. One of them died at 4 months of age due to thromboembolism in the post-operative period. One other patient, who was managed with combinations of octreotide and diazoxide, died at 3 months of age due to sepsis. Clinical characteristics and gene mutations of these patients were summarized in Table [1](#Tab1){ref-type="table"}.Table 1Clinical characteristics and genetic mutations of 23 Iranian patients with hyperinsulinaemic hypoglycaemiaPatient numberGender (F = female, M = male)Gestation-termBirth weight (g)Age of onset of hypoglycaemiaEpilepsyNeurodevelopmental delayConsanguineous parentsTreatmentGenotypeMutationMaternal/paternal genotypeFollow upDiazoxide responsiveOctreotide responsivePancreatectomy*ABCC8* 1FYes3,2802 daysNoNoNoYesYesHeterozygousc.2041-21G\>A (splicing)None/heterozygousDied at 3 months of ago 2FYes3,7501 dayYesYesNoYesHomozygousp.R1494W (missense)Heterozygous/heterozygousNeeded insulin 3FYes4,2001 dayYesNoYesYesHomozygousp.W143X (nonsense)Heterozygous/heterozygousNeeded diazoxide 4FYes5,0001 dayNoNoYesYesHomozygousp.G1376R (missense)Heterozygous/heterozygousNeeded diazoxide 5MYes4,2001 dayNoNoYesYesHomozygousc.2697+5G\>A (intron 22, novel splicing)Heterozygous/heterozygousOn diazoxide 6MYes4,5001 dayNoNoYesYesHomozygousc.2697+5G\>A (intron 22, novel splicing)Heterozygous/heterozygousResolved by 4 years of ago*KCNJ11* 7MYes4,4001 dayNoNoYesYesCompound heterozygousp.P34OH (missense) and pF117del (novel in-frame)Heterozygous/heterozygousDied at 4 months of ago*HADH* 8MYes2,8603 monthsYesNoYesYesHomozygousdelA617.c (frameshift)Heterozygous/heterozygousOn diazoxide 9FYes3,0001 yearNoNoYesYesHomozygousdelA617.c (frameshift)Heterozygous/heterozygousStopped diazoxide/no relapse 10MYes2,9001 dayYesYesYesYesHomozygousdelA617.c (frameshift)Heterozygous/heterozygousOn diazoxide 11FYes3,6504 daysNoNoNoYesHomozygousdelA617.c (frameshift)Heterozygous/heterozygousOn diazoxide 12MYes3,6003 monthsYesYesYesYesHomozygousdelA617.c (frameshift)Heterozygous/heterozygousOn diazoxide 13MYes3,1001.5 monthsYesYesNoYesHomozygousdelA617.c (frameshift)Heterozygous/heterozygousOn diazoxide 14MYes2,9007.5 monthsNoNoYesYesHomozygousdelA617.c (frameshift)Heterozygous/heterozygousOn diazoxide 15FYes3,2001 dayYesNoNoYesHomozygousdelA617.c (frameshift)Heterozygous/heterozygousOn diazoxide 16MYes3,6003 monthsYesYesNoYesHomozygousdelA617.c (frameshift)Heterozygous/heterozygousOn diazoxide 17MYes3,5003 monthsYesYesNoYesHomozygousdelA617.c (frameshift)Heterozygous/heterozygousOn diazoxide 18MYes3,5003 monthsYesNoNoYesHomozygousdelA617.c (frameshift)Heterozygous/heterozygousOn diazoxideNo mutation 19MNo1,7003 yearsNoNoYesYesTapered diazoxide/no relapse 20MNo2,0501 dayYesNoNoYesOn diazoxide 21FYes2,8009 monthsNoNoNoYesOn diazoxide 22FYes3,3005 monthsYesYesYesYesOn diazoxideFYes3,7501 dayNoNoNoYesOn diazoxide

Disease causing mutations were identified in 78 % of the patients (48 % had *HADH* mutation, 26 % had *ABCC8* and 4 % had *KCNJ11* mutation) (Fig. [1](#Fig1){ref-type="fig"}). Of the five with diazoxide-unresponsive HH, three had homozygous *ABCC8* mutation, one had heterozygous *ABCC8* mutation, which was inherited from an unaffected father, and one had homozygous *KCNJ11* mutation. All three diazoxide unresponsive patients with homozygous *ABCC8* mutation were managed by subtotal pancreatectomy. One of these patients needed insulin due to hyperglycemia in the post-operative period. The other two patients were euglycemic on a small (5 mg/kg/day) dose of diazoxide. One patient with a paternally inherited mutation was treated non-surgically with octreotide and diazoxide. One patient with homozygous *KCNJ11* mutation was managed by total pancreatectomy.Fig. 1Summary of the genotype--phenotype correlation and long term outcome.

Interestingly two patients with a novel homozygous intronic *ABCC8* mutation were diazoxide responsive and HH resolved by 4 years of age in one of the two patients. The mechanism of this is not clear.

The same homozygous *HADH* mutation was identified in 11 children with diazoxide-responsive HH \[frameshift mutation c.617delA, which is a deletion of an A nucleotide at position 617 and is predicted to result in a premature termination at codon 219 (p.K206fsX14)\]. This included two affected siblings in two different families. Eight (72 %) children with *HADH* mutation had a history of hypoglycemia following protein-rich meals, although no formal protein load test was done in these patients.

Infants with *ABCC8*/*KCNJ11* mutations were heavier at birth in comparison to the patients with *HADH* mutation (4,190 ± 550 g vs. 3,255 ± 318 g, P = 0.002). The mean age of presentation of patients with a *HADH* mutation was 99.1 days in comparison to 1.14 days in patients with *ABCC8* mutations; the difference was statistically significant (P = 0.004).

Discussion {#Sec5}
==========

In this study, 78 % of patients with HH from Isfahan, Iran were noted to have disease-causing mutations. It is very interesting to note that *HADH* mutation was the commonest genetic cause in this cohort (48 %) as opposed to the *ABCC8* mutations, which was noted only in 26 % of patients. The higher incidence of patients with *HADH* mutation accounted for the higher rate of diazoxide responsiveness in this group (78 %). All diazoxide-unresponsive patients in this series had identifiable mutations (*ABCC8/KCNJ11*), whilst no mutation was identified in 28 % of diazoxide-responsive patients.

In contrast to these observations, several other studies suggest a major role of K~ATP~ channel in the pathogenesis of patients with HH \[[@CR19], [@CR21], [@CR23]\]. In a large series of 417 patients with HH, mutations were identified in 91 % of diazoxide-unresponsive probands, and in 47 % of diazoxide-responsive patients \[[@CR20]\]. However, only 2 cases (4 % of diazoxide-responsive probands) were positive for *HADH* mutation. In another large series involving 300 patients with HH \[[@CR19]\], mutations were identified in 45.3 % of patients and *ABCC8/KCNJ11* mutations were noted to be the commonest. Among the 22.4 % of patients who had mutations in the diazoxide responsive group, only 3 patients (1 % of all cases) had *HADH* mutation \[[@CR19]\].

In keeping with previous observation \[[@CR14], [@CR19], [@CR20]\], all patients with *HADH* mutation in this group were diazoxide responsive, whilst the majority of patients (71 %) with *ABCC8/KCNJ11* mutations were diazoxide-unresponsive. As shown previously, patients with *HADH* mutation were diagnosed later and were of normal birth weight in comparison to *ABCC8* mutations \[[@CR19], [@CR24]\].

The clinical presentation of patients with heterozygous (autosomal dominant) *ABCC8* mutations is variable, ranging from mild medically responsive forms to severe early-onset HH and the vast majority of patients who do not respond to diazoxide have homozygous *ABCC8* mutations \[[@CR20]\]. We observed that three of the five patients with severe HH had homozygous *ABCC8* mutations. Interestingly a novel homozygous *ABCC8* mutation was identified in two patients with a mild form of HH that resolved completely. The precise mechanism of the course of HH in these patients is unclear.

Genetic analysis of *HADH* is generally suggested in patients with diazoxide responsive HH from consanguineous families, who are negative for mutations in the K~ATP~ channels \[[@CR18]\]. The Iranian population like some other populations, has a high level of consanguinity \[[@CR22]\]. A higher rate of consanguineous marriages may favor the onset and increased frequency of autosomal recessive diseases in a population \[[@CR22]\]. Parental consanguinity was observed in 45 % (5/11) of patients with HADH mutation in our cohort. Hence the higher incidence of HADH mutation in our group of patients is very likely related to the higher rate of consanguineous marriages in these families. Also 80 % (4/5) of children with homozygous *ABCC8* mutation had consanguineous parents.

Our results showed neurodevelopmental deficits in 30 % of the patients and epilepsy in 52 % of all cases. The prevalence of mental retardation and epilepsy was reported to be 31 and 15 %, respectively in a group of patients with HH in Austria \[[@CR25]\]. Long-term follow up of 114 patients with HH showed poor general outcome with a high degree of psychomotor or mental retardation (44 %) or epilepsy (25 %) \[[@CR26]\]. Another study from Argentina reported neurological impairment in 38 % of children with HH \[[@CR27]\], whereas a study from Greece which followed up 13 HH patients reported a good neurological outcome without any psychomotor retardation \[[@CR28]\]. It is well known that neonatal hypoglycemia is associated with neurodevelopmental complications \[[@CR29]--[@CR31]\].

Our study has several limitations. Firstly it includes a small number of patients from Isfahan, which may not be representative of the whole Iranian population. Secondly the data was collected on a retrospective basis from the medical records. Finally, an 18-F DOPA PET/CT scan was not available to differentiate focal from diffuse lesion.

Conclusion {#Sec6}
==========

This study first of its kind from Iran, demonstrates disease-causing mutations in 78 % of HH patients from Isfahan. Majority of these patients (78 %) responded to medical therapy with diazoxide. A high rate (48 %) of *HADH* mutation is seen in this population that might be attributed to a high rate of consanguineous marriages. Data shows a suboptimal long-term outcome with a high degree of neurodevelopmental deficits and epilepsy in these patients. Further research with a larger number of patients is necessary to identify the mechanism(s) of HH in Iranian population.

GCK

:   glucokinase

GDH

:   glutamate dehydrogenase

HI/HA

:   hyperinsulinism--hyperammonaemia syndrome

HH

:   hyperinsulinaemic hypoglycaemia

HADH

:   hydroxyacyl-coenzyme A dehydrogenase

HNF

:   hepatocyte nuclear factor

MLPA

:   multiplex ligation-dependent probe amplification

MODY

:   maturity onset diabetes of the young

PCR

:   polymerase chain reaction

K~ATP~

:   potassium ATP channel

SUR

:   sulphonylurea receptor

AH, MH, MH and MS collected the data and prepared the first draft. SEF and SE carried out the molecular genetic studies. AH performed the statistical analysis. SS and KH participated in the design of the study and revision of the manuscript. All authors read and approved the final manuscript.

Acknowledgements {#d30e1950}
================

None.

Compliance with ethical guidelines {#d30e1955}
==================================

**Competing interests** The authors declare that they have no competing interests.
